Ancillary Studies to Large Ongoing Clinical Projects (R01) | Apply Online

Opportunity Summary:

The Ancillary Studies to Large Ongoing Clinical Projects (R01) funding opportunity (RFA-AR-11-012) is a National Institutes of Health (NIH) grant program from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Its central goal is to pay for time-sensitive ancillary research that can be layered onto an existing large clinical effort that is already underway. Instead of building a new cohort or launching a standalone trial from scratch, applicants are expected to "plug in" a well-justified additional study to a parent project that already has the patients, systems, data flow, and often stored biospecimens needed to answer an important NIAMS-relevant scientific question quickly and efficiently. The intent is to leverage substantial prior investments in major clinical studies and registries and increase the scientific yield of those efforts.

To fit the FOA, the proposed ancillary study must be connected to a large, ongoing clinical project that is privately or publicly funded. NIAMS describes acceptable parent projects as large clinical trials, observational studies, or disease registries, as long as they provide a sufficiently sized and well-characterized cohort, plus the practical infrastructure needed to execute additional work (for example, recruitment and follow-up mechanisms, clinical sites, standardized data collection, and access to biological samples). The ancillary project is expected to enhance the value of the parent study, not derail it. In practice, this means the ancillary work should be designed to take advantage of the parent study's population and operations, adding measurements, analyses, or sub-studies that deepen understanding of diseases and organ systems within the NIAMS mission and help move the field toward improved diagnosis, treatment, or prevention.

A defining feature of this announcement is its emphasis on urgency and feasibility within the remaining lifespan of the parent project. Each application has to include a clear timeline showing that the parent study has enough time left to accommodate the additional research activities (such as extra visits, extra specimen collection, add-on imaging, new assays performed on banked samples, or additional data linkages). Applicants also must explain why the proposed work is time sensitive and why it requires an expedited review and award pathway. This is not a generic "ancillary study" mechanism; it is targeted at situations where waiting for a standard grant cycle would likely cause the opportunity to be missed (for example, because follow-up is ending soon, samples are only available during a narrow window, or a key data collection time point is imminent).

Because the ancillary study depends on access to the parent project's participants, data, and/or biospecimens, the FOA requires documentation that the parent project gives permission for that use. In other words, it is not enough to propose a scientifically attractive add-on; the application must show that the parent project leadership has agreed to allow access to the cohort and relevant resources and that the logistics of doing so are realistic. This expectation underscores NIAMS's focus on practical execution and rapid start-up.

The support mechanism is the NIH Research Project Grant (R01). The FOA also notes that it runs in parallel with a companion announcement of the same scientific scope that uses the R21 exploratory/developmental mechanism (RFA-AR-11-013). Together, these two announcements were intended to fund a small set of high-value add-on studies that can quickly capitalize on ongoing clinical investments.

For funding, NIAMS anticipated committing about $1.5 million in total costs in fiscal year 2011 to support a combined total of about four to six awards across both the R01 and R21 versions of the program. Awards were contingent on the availability of funds and the quality and number of meritorious applications received. The listing includes an award ceiling of $250,000 (as provided in the source data for this opportunity).

The opportunity fell under the health funding activity category and is associated with CFDA number 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research). It did not require cost sharing or matching. Key dates in the posting show it was posted on September 1, 2010, with an original and current closing date of April 1, 2011, and it was archived on May 2, 2011.

Eligibility was broad and included many types of domestic and non-domestic organizations. Eligible applicants listed include state and local governments (including counties, cities/townships, and special district governments), federally recognized tribal governments and other tribal organizations, public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (both with and without 501(c)(3) status), small businesses and other for-profit organizations (other than small businesses), independent school districts, public housing authorities/Indian housing authorities, and additional categories such as U.S. territories or possessions, regional organizations, and foreign organizations. The opportunity also explicitly referenced categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations, reflecting NIH's generally inclusive eligibility framework for research institutions and partners capable of conducting the proposed work.

In plain terms, this FOA was designed for research teams who could identify an important NIAMS-relevant question that can be answered by adding a focused, well-integrated set of measurements or analyses to a large clinical study that is already in motion. The program prioritizes high scientific payoff, strong justification for urgency, clear evidence that the parent study can accommodate the add-on within its remaining timeline, and documented access to the cohort and materials needed to execute the ancillary research quickly.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Ancillary Studies to Large Ongoing Clinical Projects (R21)

Previous opportunity: 2010 Grants to States for Health Insurance Premium Review Cycle I (re release)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA AR 11 012

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA AR 11 012) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA AR 11 012", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.